SARS-CoV-2 attaches to its host receptor,angiotensin-converting enzyme 2( ACE2), via the receptor-binding domain (RBD) of the spike protein. The RBD glycoprotein is acritical target for the development of neutralizing antibodies and vaccines against SARS-CoV-2. However,t he high heterogeneity of RBD glycoforms may lead to an incomplete neutralization effect and impact the immunogenic integrity of RBD-based vaccines.Investigating the role of different carbohydrate domains is of paramount importance.U nfortunately, there is no viable method for preparing RBD glycoproteins with structurally defined glycans.H erein we describe ah ighly efficient and scalable strategy for the preparation of six glycosylated RBDs bearing defined structure glycoforms at T323, N331, and N343. Ac ombination of modern oligosaccharide,peptide synthesis and recombinant protein engineering provides ar obust route to decipher carbohydrate structurefunction relationships.